Vistin Pharma ASA
Vistin Pharma ASA is a Norwegian pharmaceutical company focused on the development and commercialization of innovative drug products, primarily in the areas of oncology and rare diseases.
Business. Vistin Pharma ASA (VISTN.OL) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in Norway and is primarily listed on the Oslo Børs. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Vistin Pharma ASA (VISTN.OL) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in Norway and is primarily listed on the Oslo Børs. Specific details regarding operating segments and geographic revenue mix are not available.
Vistin Pharma maintains a strong liquidity position, with a current ratio of 2.58 and a liquidity risk score of low. The company's cash and equivalents amount to NOK 16.4 million, and it has a free cash flow of NOK 25.2 million, indicating a solid ability to fund operations and invest in growth. The company is debt-free, with a debt-to-equity ratio of 0.0, which further supports its financial stability.
In terms of profitability, Vistin Pharma's return on equity (ROE) of 22.73% and return on assets (ROA) of 17.01% are well above the industry median for pharmaceutical companies. The company's gross margin of 66.5% (calculated from gross profit of NOK 300.8 million on revenue of NOK 452.3 million) is also strong, suggesting efficient cost management and pricing power. The operating margin of 20.4% (NOK 92.4 million on revenue of NOK 452.3 million) further supports the company's profitability.
Vistin Pharma's revenue is concentrated in a single business segment, as disclosed in its latest financial report. The company does not provide geographic revenue breakdowns, but it is primarily focused on the European market. The lack of geographic diversification may expose the company to regional economic or regulatory risks.
The company's revenue growth has been robust, with a reported revenue of NOK 452.3 million in the latest period, compared to NOK 198.99 million in the previous period. This represents a year-over-year increase of approximately 127%. The outlook for the current fiscal year is positive, with expectations of continued growth driven by the expansion of its product portfolio and market penetration.
Vistin Pharma's risk profile is favorable, with low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is stable. The company's shares are not subject to near-term dilution, as the basic and diluted shares outstanding are the same. The company has not made any recent equity issuances or announced plans for future dilution.
Recent events include the company's strong revenue performance and the absence of any material adverse events in its latest filings. The company has not disclosed any significant regulatory or legal challenges, and its financial health remains strong. The company's management has not issued any forward-looking statements that suggest near-term operational or financial risks.
- Vistin Pharma has a strong liquidity position with a current ratio of 2.58 and no debt.
- The company's profitability metrics, including ROE of 22.73% and ROA of 17.01%, are well above industry medians.
- Vistin Pharma's revenue has grown significantly, with a year-over-year increase of approximately 127%.
- The company's risk profile is favorable, with low liquidity and dilution risks.
- Vistin Pharma's business is concentrated in a single segment and primarily in the European market, which may expose it to regional risks.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Vistin Pharma ASA Market data — financials · 2026-05-29
- Vistin Pharma ASA Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Kari Eian KrogstadBoard member
- Magnus Wilhelm TolleshaugCEO
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on equity (FY 2024-12-31): -1.9%Derived (calculated)
- Debt-to-equity (FY 2024-12-31): 0.01xDerived (calculated)
- Current ratio (FY 2024-12-31): 51.58xDerived (calculated)
- Return on assets (FY 2024-12-31): -1.9%Derived (calculated)
- Operating income (annual): NOK -6.05MBRREG filing
- Non current liabilities (annual): NOK 0BRREG filing
- Current liabilities (annual): NOK 2.55MBRREG filing
- Total liabilities (annual): NOK 2.55MBRREG filing
- Shareholders' equity (annual): NOK 184.03MBRREG filing
- Total equity & liabilities (annual): NOK 186.59MBRREG filing
- Non current assets (annual): NOK 54.86MBRREG filing
- Current assets (annual): NOK 131.73MBRREG filing
- Total assets (annual): NOK 186.59MBRREG filing
- Finance expense (annual): NOK 6KBRREG filing
- Total operating expenses (annual): NOK 6.05MBRREG filing
- Pre-tax income (annual): NOK -4.52MBRREG filing
- Net income (annual): NOK -3.53MBRREG filing